Search clinical trials for: Sitagliptin-placebo

Total 54402 results

Merck Sharp & Dohme LLC

Completed

ALPHA Sitagliptin Add on to Metformin (0431-103)

Diabetes Mellitus
Guangwei Li

Completed

Contribution of Pancreatic αcells Function to Blood Glucose Regulation in Chinese Type 2 Diabetics- the Effect of Sitagliptin on Glucagon Secretion, Insulin Secretion and Insulin Resistance in Chinese Type 2 Diabetics

Insulin Resistance | Insulin Secretion

China
Merck Sharp & Dohme LLC

Completed

Januvia Re-examination Study (MK-0431-181)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study of MK0431 in Patients WIth Hepatic Insufficiency (0431-017)(COMPLETED)

Liver Insufficiency
JW Pharmaceutical

Completed

Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone (CWP-DIANA-302)

Type 2 Diabetes Mellitus

Korea, Republic of
Institut National de la Santé Et de la Recherche...

Terminated

A Pilot Study Evaluating Safety of Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin in Chronic Hepatitis C Patients

Hepatitis C

France
Novartis Pharmaceuticals

Completed

Vildagliptin Versus Sitagliptin - Differences in Fasting Plasma Glucose Lowering Efficacy (FPG-VISIT)

Diabetes Mellitus Type 2

Germany
University of Colorado, Denver

Completed

Assessing Glucose Effects of Sitagliptin (Januvia) in Adult Patients With Type 1 Diabetes

Type 1 Diabetes

United States
Boehringer Ingelheim

Completed

Relative Bioavailability of Two Fixed Dose Combination Tablets of Linagliptin/Pioglitazone Compared With Single Linagliptin and Pioglitazone Tablets Administered Together to Healthy Male and Female Subjects

Healthy
GRADE Study Group
Bristol-Myers Squibb; National Institute of Diabetes and Digestive and Kidney... and other collaborators

Completed

A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes (GRADE)

Type 2 Diabetes | Comparative Effectiveness of Glycemia-lowering Medications

United States
AstraZeneca

Completed

Study in Healthy Subjects to Measure Amount of Drug in Blood After Dosing With Different Saxagliptin / Metformin Produc

Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin

United States
Augusta University
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Estrogen and Diabetes

Diabetes Mellitus, Type 1

United States
Profil Institut für Stoffwechselforschung GmbH

Completed

A Study to Investigate the Glucose Lowering Effects of Dextromethorphan Alone or in Combination With Sitagliptin in Subjects With Type 2 Diabetes Mellitus (T2DM) After an Oral Glucose Tolerance Test (DXM2)

Type 2 Diabetes Mellitus

Germany
Sabyasachi Sen

Terminated

Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes Mellitus

Cardiovascular Diseases | Diabetes Mellitus, Type 2

United States
Nick Giannoukakis, PhD
University of South Florida; AstraZeneca; University of Pittsburgh; National Institutes...

Completed

Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes

Type 2 Diabetes Mellitus | Insulin Resistance

United States
AstraZeneca

Completed

Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants

Type 2 Diabetes Mellitus

United States
University of Oklahoma

Completed

Sitagliptin Treatment in Patients With Type 2 DM After Kidney Transplant

Type 2 Diabetes | Kidney Transplant

United States
University College Dublin

Completed

Dipeptidyl Peptidase-4 Inhibition and Narrow-band Ultraviolet-B Light in Psoriasis (DINUP) (DINUP)

Psoriasis

Ireland
Ono Pharmaceutical Co. Ltd

Completed

Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Cadila Pharnmaceuticals
New Millennium Indian Technology Leadership Initiative (NMITLI) program of...

Completed

Effect of CPL-2009-0031 in the Treatment of Patients With Uncontrolled Type 2 Diabetes Mellitus

Uncontrolled Type 2 Diabetes Mellitus

India
Merck Sharp & Dohme LLC

Completed

An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024)

Diabetes Mellitus, Type 2
Forest Laboratories
Phenomix

Terminated

Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone (REDWOOD403)

Diabetes Mellitus, Type 2

United States
Boehringer Ingelheim

Completed

Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food

Healthy

Germany
University Health Network, Toronto
Novo Nordisk A/S

Enrolling by invitation

Semaglutide vs Sitagliptin

Diabetes Mellitus | NAFLD | NASH - Nonalcoholic Steatohepatitis | Liver Transplant; Complications

Canada
University Medical Centre Ljubljana

Completed

Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance and Type 2 Diabetes in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome

PCOS
Merck Sharp & Dohme LLC

Completed

Sitagliptin/Metformin (JANUMET) Re-examination Study (0431A-182)

Type 2 Diabetes Mellitus
Boehringer Ingelheim

Completed

Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone

Diabetes Mellitus, Type 2

Austria, Greece, Hungary, Japan, Portugal, Romania, Spain
Boryung Pharmaceutical Co., Ltd

Completed

A Clinical Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Fimasartan and Linagliptin in Healthy Volunteers

Hypertension | Diabetes

Korea, Republic of
Shahid Beheshti University of Medical Sciences
Isfahan University of Medical Sciences

Completed

Iranian Intensive Care Unit (ICU) Glutamine Study

Trauma Patients in ICU

Iran, Islamic Republic of
Boehringer Ingelheim

Completed

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single and Multiple Doses of Linagliptin Tablets in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function

Renal Insufficiency
Boehringer Ingelheim

Completed

Treatment of Type 2 Diabetes With Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid and Metformin 1000 mg Bid

Diabetes Mellitus, Type 2

Canada, Croatia, Estonia, France, Germany, India, Lithuania, Mexico, Netherlands, Romania, Russian Federation, Sweden, Tunisia, Ukraine
Genuine Research Center, Egypt
Eva Pharma

Completed

Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

Healthy

Egypt
Boehringer Ingelheim

Completed

Bioequivalence of a Fixed Dose Combination Tablet Linagliptin/Pioglitazone Compared With Its Mono-components

Healthy

Germany
University of Copenhagen
Hvidovre University Hospital

Completed

Effect of Neprilysin on Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes (NEPT2D)

Type2 Diabetes

Denmark
AstraZeneca

Completed

Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea

Type 2 Diabetes Mellitus | Inadequate Glycaemic Control

Germany, Slovakia, Czechia, Hungary, Poland
AstraZeneca

Completed

Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone

Diabetes Mellitus, Type 2

United States, Chile, Argentina, Brazil, Canada, Mexico, Puerto Rico, Taiwan, Australia
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin/Metformin Compared With Single Tablets

Healthy

United States
Third Military Medical University

Completed

Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP) (ESCDP)

Diabetes Mellitus, Type 2 | Cognitive Functions Confusion

China
Hospital de Especialidades, Centro Medico Nacional...
National Polytechnic Institute, Mexico

Completed

SITAgliptin Plus GLARgine to Glycemic Control in the Hospital Setting (SITAGLAR-H) (SITAGLAR-H)

Type 2 Diabetes

Mexico
Getz Pharma

Completed

Monitoring Parameters Beyond Glycemic Control: Impact of Sitagliptin on Quality of Life in Type 2 Diabetes Patients (DQOL)

Quality of Life | Type 2 Diabetes | Metformin+Sitagliptin

Pakistan
Karolinska Institutet

Completed

Beta-cell Function in Glucose Abnormalities and Acute Myocardial Infarction (BEGAMI)

Myocardial Infarction | Diabetes Mellitus | Impaired Glucose Tolerance | Unstable Angina Pectoris

Sweden
University of Leicester
Novo Nordisk A/S; University Hospitals, Leicester

Completed

Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA) (LYDIA)

Cardiovascular Disease | Type 2 Diabetes Mellitus

United Kingdom
CHEOL WHAN LEE, M.D., Ph.D

Completed

Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery Disease (ELITE)

Coronary Disease | Diabetes Mellitus

Korea, Republic of
Tehran University of Medical Sciences

Completed

Sitagliptin vs. Pioglitazone as add-on Treatments in Patients With Type 2 Diabetes Uncontrolled on the Full-dose Metformin Plus Sulfonylurea

Uncontrolled Type 2 Diabetes Mellitus

Iran, Islamic Republic of
Novo Nordisk A/S

Completed

The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, Puerto Rico, United Kingdom, Ireland, Germany, Slovenia, Canada, France, Italy, Spain, Netherlands, Slovakia, Romania, Former Serbia and Montenegro
University Medical Centre Ljubljana

Completed

Weight Maintenance With Dipeptidyl Peptidase 4 (DPP4) Inhibitor Sitagliptin in Combination With Metformin After Liragludite Induced Weight Loss

Polycystic Ovary Syndrome | Body Weight
Merck Sharp & Dohme LLC

Completed

A Study on the Effect of Kidney Disease on a Diabetes Medication (0431-008)

Renal Insufficiency | Hemodialysis
Seoul National University Bundang Hospital

Completed

Predictive Parameters for Efficacy of Sitagliptin and Metformin Combination (COSMETIC)

Diabetes

Korea, Republic of
Joslin Diabetes Center

Enrolling by invitation

Oral Hypoglycemic Therapy for Monogenic Variant Carriers of the Joslin Medalist Study

Type 1 Diabetes | Monogenic Diabetes

United States
Brigham and Women's Hospital

Completed

Replication of the GRADE Diabetes Trial in Healthcare Claims Data

Diabetes

United States

3

Subscribe